CellCarta and Leica Biosystems expand push to streamline precision medicine development

The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments

Ebola vax on the anvil?

CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate

Zydus’ Saroglitazar wins FDA priority review after strong Phase 3 results in liver disease trial

The therapy also delivered significant improvements in key liver enzyme markers

Pfizer and Innovent Biologics strike $10 billion cancer drug deal

This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants

Europe Treponema pallidum tests market to grow at 3% CAGR through 2036

Increasing syphilis cases, stronger STI surveillance initiatives, and growing emphasis on early diagnosis are expected to support sustained demand

Pantherna acquisition to boost T-CURX’s clinical translation of non-viral In Vivo CAR-T strategies

Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier

Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting

The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial

Glenmark posts strong FY26 results with 27.5% revenue jump

India’s MedTech industry is entering its defining decade: Dr. Shravan Subramanyam, MD, BPL Medical Technologies

From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies

Asahi Kasei bags breakthrough ADC tech in push for safer & more precise cancer therapies

The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs